Entrada After the Selloff: Why the Dystrophin Miss May Be a Tradeable Entry
Entrada Therapeutics cratered after a modest dystrophin readout, but the stock now trades at $5.67 with a market cap of $221M, cash runway into Q3 2027, and a Data Monitoring Committee that has green-lit a higher dose for its exon-45 program. For traders willing to accept clinical and financing risk, this is an actionable long with a tight stop and…